Author

S. Perez-Yanes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Blanco· 3 shared A. Valenzuela-Fernandez· 2 shared C. Casado· 2 shared C. Rovirosa· 2 shared J. Estevez-Herrera· 2 shared M. Pernas· 2 shared R. Cabrera-Rodriguez· 2 shared S. Marfil· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. Blanco

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Transactive response DNA-binding Protein (TDP-43) regulates early HIV-1 entry and infection.

R. Cabrera-Rodriguez, S. Perez-Yanes, R. Gonzalez-Montelongo, J. M. Lorenzo-Salazar, J. Estevez-Herrera, J. Garcia-Luis, A. Inigo-Campos, L. A. Rubio-Rodriguez, A. Munoz-Barrera, R. Trujillo-Gonzalez, R. Dorta-Guerra, C. Casado, M. Pernas, J. Blanco, C. Flores, A. Valenzuela-Fernandez

This study shows that TDP-43 regulates HIV-1 infection by stabilizing HDAC6, reducing viral Env fusion and infection capacity in CD4+ T cells.

bioRxiv · Dec 6, 2021 · PreprintImmunology

The characteristics of the HIV-1 Env glycoprotein contribute to viral pathogenesis

S. Perez-Yanes, M. Pernas, S. Marfil, R. Cabrera-Rodriguez, R. Ortiz, C. Rovirosa, J. Estevez-Herrera, I. Olivares, C. Casado, C. Lopez-Galindez, J. Blanco, A. Valenzuela-Fernandez

This study examines how HIV-1 Env glycoprotein characteristics correlate with viral pathogenesis by comparing functional and sequence features across different clinical progression groups.

bioRxiv · Jul 7, 2021 · PreprintMicrobiology

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

E. Pradenas, B. Trinite, V. Urrea, S. Marfil, C. Avila-Nieto, M. L. Rodriguez de la Concepcion, F. Tarres-Freixas, S. Perez-Yanes, C. Rovirosa, E. Ainsua-Enrich, J. Rodon, J. Vergara-Alert, J. Sagales, V. Guallar, A. Valencia, , J. Blanco

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

bioRxiv · Nov 22, 2020Immunology